1 Min Read
(Reuters) - Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N), Canada's biggest public drugmaker, reported an 81 percent drop in third-quarter profit, and the company cut its profit forecast for the current quarter.
Net income fell to $7.6 million, or 2 cents per share, from $40.9 million, or 13 cents per share, a year earlier.
Total revenue rose 47 percent to $884.1 million. (Reporting by Bhaswati Mukhopadhyay in Bangalore and Allison Martell in Toronto; Editing by Sriraj Kalluvila)